Treatment outcomes of combination of anti-vascular endothelial growth factor injection and laser photocoagulation in Type 1 ROP and APROP
Author:
Publisher
Springer Science and Business Media LLC
Subject
Ophthalmology
Link
https://link.springer.com/content/pdf/10.1007/s10792-021-02004-8.pdf
Reference31 articles.
1. Steinkuller PG, Du L, Gilbert C, Foster A, Collins ML, Coats DK (1999) Childhood blindness. J AAPOS 3(1):26–32. https://doi.org/10.1016/s1091-8531(99)70091-1
2. Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) BEAT-ROP Cooperative group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364(7):603–615. https://doi.org/10.1056/NEJMoa1007374
3. Kychenthal A, Dorta P, Katz X (2006) Zone I retinopathy of prematurity: clinical characteristics and treatment outcomes. Retina 26(7):S11–S15. https://doi.org/10.1097/01.iae.0000244285.79004.e6
4. Hård AL, Hellström A (2011) On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment: a review. Acta Paediatr 100(12):1523–1527. https://doi.org/10.1111/j.1651-2227.2011.02445.x
5. Avery RL (2012) Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both? J AAPOS 16(1):2–4. https://doi.org/10.1016/j.jaapos.2011.11.002
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Latest Trends in Retinopathy of Prematurity: Research on Risk Factors, Diagnostic Methods and Therapies;International Journal of General Medicine;2023-03
2. Role of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) in the Treatment of Retinopathy of Prematurity: A Narrative Review in the Context of Middle-Income Countries;Pediatric Health, Medicine and Therapeutics;2023-02
3. One year follow-up of intravitreal bevacizumab injection in Aggressive Retinopathy of Prematurity at Indonesian national referral hospital: Case series;Annals of Medicine & Surgery;2022-12
4. Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies for Retinal Angiogenesis;Drug Design, Development and Therapy;2022-09
5. OUTCOME OF THE MANAGEMENT OF AGGRESSIVE RETINOPATHY OF PREMATURITY (A-ROP);INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH;2022-04-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3